

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HU et al.

Application Serial No.: 09/935,726

Art Unit: 1647

Filing Date: August 24, 2001

Examiner: To be assigned

Title: Vascular Endothelial Growth Factor 2

Atty. Docket No.: PF112P3D1C1



STATEMENTS UNDER 37 C.F.R. § 1.825(a) AND (b)

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants herewith submit a paper copy of a Substitute Sequence Listing (20 pages) and, a computer-readable diskette containing the Substitute Sequence Listing. The Substitute Sequence Listing (paper copy and computer readable form (CRF)) is submitted herewith to comply with current format requirements under 37 C.F.R. § 1.823 and § 1.824.

As such, in accordance with 37 C.F.R. § 1.825(a), the undersigned attorney for Applicants hereby states that sequence information contained in the Substitute Sequence Listing submitted herewith is identical to the sequence information contained in the Sequence Listing of the specification as originally filed. Therefore, the Substitute Sequence listing is completely supported by the specification as originally filed, and no new matter has been introduced.

In accordance with 37 C.F.R. § 1.825(b), the undersigned attorney for Applicants hereby states that the information in the paper copy of the Substitute Sequence Listing submitted herewith is identical to the information contained in the computer readable form of the Substitute Sequence Listing submitted herewith.

Respectfully submitted,

Dated: Jan 25, 2002

Michele M. Wales
Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772

Enclosures
MMW/AKR/lcc